Committee Will Sift Through 'Noise' Associated With Nuplazid Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is concerned the change shown by Acadia's proposed Parkinson's psychosis product may not be clinically meaningful.
You may also be interested in...
Acadia’s Persistence With Pimavanserin In Parkinson’s Psychosis Pays Off
After meeting with FDA, Acadia announces it needs only one pivotal study for pimavanserin. The company has canceled a second study and expects to file at the end of 2014. Faster NDA pathway could mean launch a year earlier than expected.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.